Company: GRCE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001140361-25-041804
Chunk: 12

Company: Grace Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Item 8
Chunk 12
---
 Plan.  
   The following table summarizes information about activities within the 2024 Plan and Prior Plans for the six months ended September 30, 2025:  
                          Number   of
   Options      Weighted-average   Exercise Price      Remaining   Contractual Term   (years)      Aggregate Intrinsic   Value (in   thousands)              $         $     Outstanding, March 31, 2025    934,923    3.52    8.26    24     Granted    391,530    2.15    9.55    327     Forfeited/Cancelled    (16,750)    2.83               Outstanding, September 30, 2025    1,309,703    3.12    8.30    600     Exercisable, September 30, 2025    768,057    3.65    7.80    267    
   The weighted-average grant date fair value of awards for options granted during the six months ended September 30, 2025 was $1.78. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted-average assumptions for the options granted:  
         Six months ended   September 30, 2025      Six months ended   September 30, 2024          Weighted-average      Weighted-average      Exercise price   $2.15   $2.96     Share price   $2.15   $2.96     Dividend     —      —      Risk-free interest    4.02%   4.43%    Estimated life (years)    5.74    5.81     Expected volatility    109.43%   114.37%  

  17
  

 Compensation expense recognized under the 2024 Plan and the Prior Plan is summarized as follows:  

      Three months ended
     
      Six months ended

      September 30, 2025

      September 30, 2024

      September